1. Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

2. Characteristics of new users of statins, by persistence and average dose of statin use during the first 2 years of treatment F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

3. Effect of persistence and dose of statin use during the first 2 years of treatment on risk of hospitalization for myocardial infarction, by type of prevention F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

4. Equipotency and percentage reduction in total cholesterol according to the different types and doses of statins F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

5. Type, dose, and equipotency of the statin last prescribed before the start of outcome follow-up in 2-year persistent users, by average equipotent dose during the first 2 years of treatment F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159